#EULAR2024 LBA0001 New Steroid-sparring therapy for #GCA. Phase 3 RCT showed Upadacitinib 15mg met primary endpoint (sustained clin remission frm Wks 12-52 & adherence to 26Wk GC taper) vs PBO [46% vs 29%] & multiple secondary endpoints. No new safety signals @RheumNow https://t.co/edfSZkMuy2

• https://twitter.com/Yuz6Yusof/status/1801890562221466088/photo/1

LBA0001 UPA in GCA- Phase 2 RCT 15mg UPA with 26w steroid taper showed ⬆️ efficacy ⬇️ steroid use vs placebo with 52w steroid taper Potential new target on the horizon for #GCA?? @RheumNow #EULAR2024

#EULAR2024 POS0417 Using EXPLORE Inflammation I & II proteomics, marked immune dysregulation was seen in new ANA+ referral vs HC. 34% progressed to #lupus & #Sjogren. Six potential baseline biomarkers identified & closely resembled established SLE. Validation is ongoing @RheumNow https://t.co/I6HygqNwf7

• https://twitter.com/Yuz6Yusof/status/1801887094282789134/photo/1

Nipocalimab (anti-FcRn - i.e. PLEX-in-a-bottle) with a positive phase 2 in Sjogren’s. This study is in high systemic dx pts (with nice response matching biological plausibility) - but salivary flow improved too ESSPRI didn’t quite make it, but close #EULAR2024 LBA0010 @RheumNow https://t.co/PslFKJBOOr

• https://twitter.com/drdavidliew/status/1801886350591099208/photo/1
• https://twitter.com/drdavidliew/status/1801886350591099208/photo/1
• https://twitter.com/drdavidliew/status/1801886350591099208/photo/1
• https://twitter.com/drdavidliew/status/1801886350591099208/photo/1

EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMIZED, DB,PBO CONTROLLED, MULTICENTER 2b/3 STUDY ACR responses 60:40:20 42% MDA PASI 100 47% ho hum same as others-how many IL17s do we need ? @RheumNow #EULAR2024

Points to consider in pregnancy &lactation in Pts w #rheumatic #diseases #biologics don’t increase rate of serious infections in Mom Baby Compared to other matched pregnant and post partum women reassuring! #EULAR2024 @RheumNow @eular_org

What to use in men prior to planned conception of partner in #rheumatic #diseases #EULAR2024 ⁦@RheumNow⁩ ⁦@ACRheum⁩ ⁦@eular_org⁩ https://t.co/jMecV8jqUe

• https://twitter.com/Janetbirdope/status/1801882605505142913/photo/1

MINIMAL SPINAL RADIOGRAPHIC PROGRESSION in RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS OVER 2 YEARS OF BIMEKIZUMAB TREATMENT: RESULTS FROM A PHASE 3 OPEN-LABEL EXTENSION STUDY - 90% nonprogressers on Bime including how many would never have progressed ? @RheumNow #EULAR2024

Points to consider in pregnancy in #rheumatic diseases 3 points ✅TNFi all OK 👍 ? Only if you can’t control disease use other #bDMARDs Baby #vaccinations if exposed to #biologics while present #rotovirus ok other live vaccines >6 mos #EULAR2024 @eular_org @RheumNow https://t.co/MyJdA7p7zh

• https://twitter.com/Janetbirdope/status/1801881956491104300/photo/1
• https://twitter.com/Janetbirdope/status/1801881956491104300/photo/1

POS0231 Safety of JAKi vs TNFi or IL-17 inhibitors in #PsA & #SpA Results from a large population-based study show reassuring data, with no increased risk of #CVD, #VTE or certain cancers compared to TNFi or IL-17i @SteZhao @RheumNow #EULAR2024

1200 PsA pts 6 countries IL17is as effective as TNFi and JAK despite more failed bDMARDs and monotherapy & faster onset action than IL23s ⁦@RheumNow⁩ #EULAR2024 https://t.co/SM5CA7KUvd

• https://twitter.com/drpnash/status/1801879213739237768/photo/1

#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B

• https://twitter.com/Yuz6Yusof/status/1801876904506478640/photo/1
• https://twitter.com/Yuz6Yusof/status/1801876904506478640/photo/1

New reccs for knee/hip #OA w/2 overarching principles 1. Biopsychosocial approach 2.Individualized Rx w/shared decision making (includes education, diet/exercise, healthy weight, appropriate assistive device/footware, modify work factors, pain coping skills) #EULAR24 @rheumnow https://t.co/0LVLBMGO7L

• https://twitter.com/KDAO2011/status/1801876488590901710/photo/1

Different pathways of auto inflammatory disease which is an amplifier system. Always check the phenotype first before genotype. Kasner D #EULAR2024 @RheumNow https://t.co/MtPzsVBNjn

• https://twitter.com/synovialjoints/status/1801875376911638774/photo/1

#EULAR2024 LBA0010 Promising Tx with diff mode of action in antibody+ #Sjogren. Phase 2 RCT Nipocalimab, anti-neonatal Fc receptor (FcRn)Ab that reduces IgG, met primary endpoint (clinESSDAI). Low SIE but doubled in lowest dose vs PBO (unrelated to IgG). On to Phase3 @RheumNow https://t.co/NlCc2l4zFL

• https://twitter.com/Yuz6Yusof/status/1801873035462328546/photo/1